LETTER TO THE EDITOR

Identification of *Schizosaccharomyces pombe* in the guts of healthy individuals and patients with colorectal cancer: preliminary evidence from a gut microbiome secretome study

Siok-Fong Chin1*, Putri Intan Hafizah Megat Mohd Azlan1, Luqman Mazlan2 and Hui-min Neoh1

Abstract

Over the years, genetic profiling of the gut microbiome of patients with colorectal cancer (CRC) using genome sequencing has suggested over-representation of several bacterial taxa. However, little is known about the protein or metabolite secretions from the microbiota that could lead to CRC pathology. Proteomic studies on the role of microbial secretome in CRC are relatively rare. Here, we report the identification of proteins from *Schizosaccharomyces pombe* found in the stool samples of both healthy individuals and patients with CRC. We found that distinctive sets of *S. pombe* proteins were present exclusively and in high intensities in each group. Our finding may trigger a new interest in the role of gut mycobiota in carcinogenesis.

Keywords: *Schizosaccharomyces pombe*, Human gut, Microbiome, Secretome, Colorectal cancer

Gut microbiome and colorectal cancer

Dysbiosis of the gut microbiome has been postulated to be the causative event in colorectal cancer (CRC). For many years, most microbiome studies focused primarily on genetic sequencing and the subsequent identification of gut bacteria; however, the role of bacteria in CRC carcinogenesis remains unclear. We hypothesised that protein secretions from these microorganisms play a role in the pathophysiology of CRC. We aimed to identify and compare the secreted proteins released from the human gut microflora by assessing the stool samples of both patients with CRC and healthy control individuals.

Faecal sample extraction and protein identification

A pilot study was performed at the endoscopy unit and surgery and medical clinics at the UKM Medical Centre, Kuala Lumpur, from 2016 to 2017. Stool samples from 26 patients with clinically diagnosed CRC and 20 non-CRC control individuals were collected from the UKM Medical Centre. The samples were homogenised and filtered, followed by precipitation with acetone, reduction with dl-Dithiothreitol, alkylation with iodoacetamide and digestion with trypsin. The resulting peptides were analysed by reverse-phase LC–ESI–MS/MS using Eksigent NanoLC system connected to a quadrupole time-of-flight 5600+ TripleTOF™ mass spectrometer (AB Sciex, USA). Briefly, mass spectra were acquired in the data-dependent mode (250 ms accumulation time per spectrum and mass range of 300–1250 m/z) to obtain MS/MS spectra for the most abundant parent ions following each survey MS1 scan. For each mass spectrum, a maximum of 50 precursors with a charge state between 2 and 4 were selected for fragmentation. The tandem mass spectrum was acquired in the high-sensitivity mode, in which the...
signals were accumulated for a minimum of 50 ms per spectrum, and the dynamic exclusion time was set at 24 s.

The mass spectrum datasets were searched using MaxQuant against the microbial UniProt Fasta database (accessed on 18 September 2017). Statistical analyses were performed using the Statistical Package for Social Sciences (SPSS) version 22. Functional and integrative analyses of the identified proteins were performed using the Database for Annotation, Visualisation and Integrated Discovery (DAVID) [1] and MetaboAnalyst 4.0 [2] online tools, respectively.

**Secretome of gut microbiome in healthy individuals and patients with CRC**

We identified 2132 proteins secreted by the gut flora (1370 from bacteria; 589 from fungi; 112 from archaea; 45 from viruses to 16 from parasites), with 96 proteins specific to CRC. In contrast, 2035 proteins were exclusive to the non-CRC controls. Only one bacterial protein from *Borrelia recurrentis* was commonly secreted in both CRC and non-CRC groups. Interestingly, we found that vast protein secretions were mapped to *S. pombe*, which were not previously reported in the human gut. *S. pombe*, a fission yeast, is traditionally used in brewing. Its 50 genes are similar to human genes associated with diseases, with 23 genes similar to human cancer genes [3]. This yeast has been widely used as a model organism to study human diseases and pathological events, such as cancer and ageing [4, 5]. To the best of our knowledge, no previous study has shown the association between *S. pombe* and human diseases.

In our study, a total of 124 proteins secreted by *S. pombe* were exclusively found in the control samples. Five proteins found in the CRC samples were successfully mapped to the yeast. The distribution of the secretome proteins identified from the yeast was skewed towards the control samples compared with the CRC samples (Fig. 1). We also observed great variation in the secretome of *S. pombe* in the studied individuals, regardless of the presence or absence of CRC or early- or late-stage CRC, as revealed by discriminant and heat-map analyses. However, all the secretome proteins from *S. pombe* identified in the CRC were of high intensity, with four proteins exclusively secreted in the late stage of CRC (DNA repair protein rhp57; SWR1 complex bromodomain subunit bdf1; structural maintenance of chromosomes protein 5 and uncharacterised WD repeat-containing protein C16H5.13). In contrast, the conserved oligomeric Golgi complex subunit 8 was secreted in the early stage of CRC.
Conclusion
The importance of mycobiota in gut health has been recently postulated. The study of these fungi may provide new therapeutic approaches. Of note, the current probiotics paradigm has shifted from the use of bacteria to yeast [6]. However, little is known about the role of these naturally occurring mycobiota in the gut microenvironment and their effects on the host (e.g., contributing to health or diseases), particularly chronic effects at the molecular level. We suggest that distinctive sets of S. pombe proteins be used as markers to distinguish between individuals with and without CRC. It is still unknown if the proteins secreted by S. pombe identified in this study result in tumorigenesis or vice versa. Thus, further investigation is warranted.

Abbreviations
CRC: colorectal cancer; S. pombe: Schizosaccharomyces pombe; SPSS: Statistical Package for the Social Sciences; DAVID: Database for Annotation, Visualisation and Integrated Discovery.

Authors’ contributions
PIHMMA and LM collected the samples; SFC and PIHMMA performed the experiment, analysed the data and drafted and wrote this manuscript; SFC and HN were responsible for idea conception, critical evaluation and manuscript review. All authors read and approved the final manuscript.

Author details
1 UKM Medical Molecular Biology Institute, Universiti Kebangsaan Malaysia, Cheras, Kuala Lumpur, Malaysia. 2 Department of Surgery, Faculty of Medicine, Universiti Kebangsaan Malaysia Medical Centre, Cheras, Kuala Lumpur, Malaysia.

Acknowledgements
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Availability of data and materials
The dataset supporting the conclusion of this article are included within the article.

Consent for publication
All authors have approved this manuscript and consented for its publication.

Ethics approval and consent to participate
The study was approved by the Research Ethics Committee of The National University of Malaysia (UKM 1.5.3.5/244/JP–2016-072). All participants have consented to participate in the study.

Funding
This work was supported by the Transdisciplinary Research Grant Scheme (TRGS/2/2014/UKM/02/3/2) from the Ministry of Higher Education (MOHE), Malaysia.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 31 May 2018 Accepted: 3 July 2018
Published online: 10 July 2018

References
1. Dennis G Jr, Sherman BT, Hosack DA, Yang J, Baseler MW, Lane HC, Lempicki RA. DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol. 2003;4(5):3.
2. Cheng J, Soufan O, Li C, Caras I, Li S, Bourque G, Wishart DS, Xia J. MetaboAnalyst 4.0: towards more transparent and integrative metabolomics analysis. Nuc Acids Res. 2018. https://doi.org/10.1093/nar/gky310.
3. Wood V, Guvrillam R, Rajandream M, Lyne M, Lyne R, Stewart A, et al. The genome sequence of Schizosaccharomyces pombe. Nature. 2002;415(6874):871–80.
4. Gangloff S, Arcangioli B. DNA repair and mutations during quiescence in yeast. FEMS Yeast Res. 2017;17(1):1–14.
5. Langerak P, Russell P. Regulatory networks integrating cell cycle control with DNA damage checkpoints and double-strand break repair. Philos Trans R Soc Lond B Biol Sci. 2011;366(1584):3562–71.
6. Palma ML, Zamith-Miranda D, Martins FS, Bozza FA, Nimrichter L, Montero-Lomeli M, Marques ETA Jr, Douradinha B. Probiotic Saccharomyces cerevisiae strains as biotherapeutic tools: is there room for improvement? Appl Microbiol Biotechnol. 2015;99(16):6563–70. https://doi.org/10.1007/s00253-015-6776-x.